Positive Safety Review Committee Recommends Advancing PAS-004 in Phase 1 Trial
Thursday, 13 June 2024, 13:28
Pasithea Therapeutics Achieves Milestone in PAS-004 Phase 1 Clinical Trial
The recent announcement by Pasithea Therapeutics signifies a major milestone in the ongoing Phase 1 clinical trial for PAS-004.
Brief Summary:
- Importance of the Announcement: signifies significant progress in the clinical trial.
- Commitment to Innovation: highlights the company's dedication to advancing novel treatments.
- Emphasis on Patient Safety: positive recommendation underscores focus on patient well-being.
Overall, Pasithea Therapeutics' latest milestone reinforces its position in the pharmaceutical sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.